市場調查報告書
商品編碼
1439236
心臟幫浦設備 - 全球市場考量、競爭狀況、市場預測 (2030)Heart Pump Device - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
全球心臟幫浦設備市場規模預計到2023年將達到27.3億美元,到2030年將達到63.5億美元,2024-2030年預測期間複合年增長率為15.16%。心臟泵設備的需求主要是由心血管疾病(CVD)盛行率的增加、老年人口的增加以及各種產品處於研發階段的公司所推動的。研究發現,心臟幫浦設備對治療 COVID-19 心臟衰竭病例非常有益,這進一步增加了疫情期間對這些設備的需求。由於缺乏心臟供應商,心臟幫浦成為驅動全球市場擴張的最佳解決方案。然而,發展中市場的泵浦成本高和還款率低等因素預計將抑制市場成長。
心泵設備市場動態
根據美國心臟協會(2022)的數據,2020 年全球約有 2.441 億人患有冠狀動脈心臟病(缺血性心臟病)。
根據英國心臟基金會(2022)提供的數據,2019年全球約有5.5億人,即每14人中就有1人患有心臟和循環系統疾病,其中包括約2.9億女性和約2.6億男性。
上述文件進一步指出,冠狀動脈心臟病、週邊動脈疾病、中風和心房顫動是2019年全球最常見且流行的心血管疾病。
根據國家衛生組織 (PAHO) (2022) 的數據,心血管疾病每年造成的死亡人數比其他任何疾病都多。2021 年,與心臟病和中風相關的死亡人數佔低收入和中等收入國家所有死亡人數的四分之三以上。
增加有關心臟泵設備的研發活動進一步促進了心臟泵設備市場的成長。例如,2022 年 8 月,Abbott宣布,根據 MOMENTUM 3 試驗的數據,其 HeartMate 3 心臟幫浦可將心臟衰竭患者的生存期延長至少五年。
因此,上述因素預計將在未來幾年推動整個心臟幫浦設備市場的發展。
然而,發展中國家的高泵成本和低還款情況可能成為心泵設備市場成長的限制因素。
心泵設備細分市場分析
在心泵設備市場的產品細分中,屬於心室輔助設備類別的左心室輔助設備(LVAD)預計將佔據最大份額,是市場上成長最快的細分市場之一。
這主要是由於與 LVAD 相關的益處和應用,以及技術進步、器官捐贈者短缺以及全球心臟衰竭盛行率的增加。
LVAD 旨在透過恢復正常血流來治療嚴重心臟衰竭患者。在心臟衰竭患者體內植入 LVAD 可以挽救生命,並為器官移植贏得時間。
LVAD 高度可靠且內建安全系統。
植入 LVAD 後,患者的健康狀況有所改善,並且能夠恢復/恢復運動和其他日常活動。
LVAD 為嚴重心臟衰竭患者提供了中長期治療方案。
因此,所有上述因素預計將推動心臟泵設備市場的成長。
北美預計將主導整個心臟幫浦設備市場。
預計在預測期內,北美將主導整個心臟幫浦設備市場。這是由於該國龐大的心血管疾病(CVD)患者群體、非常強大的產品開發和市場開發市場、較高的消費者認知度以及該地區主要市場參與者的存在,這些被認為是推動這一成長的關鍵因素。市場成長。
該報告提供了全球心臟幫浦設備市場的研究和分析,包括市場規模和預測、驅動因素和挑戰以及公司和產品概況。
Heart Pump Devices Market By Product (Ventricular Assist Devices [Left Ventricular Assist Devices (LVAD), Percutaneous Ventricular Assist Devices (PVAD), Biventricular Ventricular Assist Devices (BIVAD), and Right Ventricular Assist Devices (RVAD)], Intra-Aortic Balloon Pumps, and Total Artificial Hearts), Type (Implanted Heart Pump Device and Extracorporeal Heart Pump Device), Therapy (Bridge-To-Transplant (BTT), Bridge-To-Candidacy (BTC), and Destination Therapy (DT)), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography is expected to grow at a steady CAGR forecast till 2030 owing to rising prevalence of cardiovascular diseases (CVDs) and increasing research and development activities
The global heart pump devices market was valued at USD 2.73 billion in 2023, growing at a CAGR of 15.16% during the forecast period from 2024 to 2030, to reach USD 6.35 billion by 2030. The demand for heart pump devices is primarily motivated by the increase in cardiovascular disease (CVDs) prevalence, the rise in the geriatric population, and various companies with products in their pipeline phase. Heart Pump devices were found to be extremely beneficial in heart failure cases in COVID-19 which further pushed for the demand for these devices during the pandemic situation. Due to a scarcity of heart suppliers, cardiac pumps are an optimal solution that encourages Global market expansion. Factors such as the high cost of the pump and a low repayment scenario in developing countries are nevertheless projected to inhibit the growth of the market.
Heart Pump Devices Market Dynamics:
According to the American Heart Association 2022, about 244.1 million people were globally living with coronary (ischemic) heart disease in 2020.
As per the data provided by British Heart Foundation 2022, worldwide around 550 million which stands for 1 in 14 people were living with heart and circulatory diseases in 2019 and this includes about 290 million women and around 260 million men.
The source mentioned above further stated that coronary (ischemic) heart disease (200 million cases), peripheral arterial (vascular) disease (110 million cases), stroke (100 million cases), and atrial fibrillation (60 million cases) remained the commonest and prevalent cardiovascular conditions worldwide in 2019.
According to Pan American Health Organization (PAHO) 2022, cardiovascular diseases cause more deaths yearly than any other disease. Heart disease and stroke-related fatalities account for more than three-quarters of all deaths in low- and middle-income nations in 2021.
The increasing number of research and development activities pertaining to heart pump devices is further going to assist in the growth of the heart pump devices market. For example, in August 2022, Abbott based upon data obtained from the MOMENTUM 3 trial announced that its HeartMate 3 heart pump extends the survival of heart failure patients by at least five years.
Therefore, the afore-said factor will propel the overall market of heart pump devices in the upcoming years.
However, the high cost of the pump and low repayment scenario in developing countries may act as a restraint in the growth of the heart pump devices market.
Heart Pump Devices Market Segment Analysis:
Heart Pump Devices by Product (Ventricular Assist Devices [Left Ventricular Assist Devices (LVAD), Percutaneous Ventricular Assist Devices (PVAD), Biventricular Ventricular Assist Devices (BIVAD), and Right Ventricular Assist Devices (RVAD)], Intra-Aortic Balloon Pumps, and Total Artificial Hearts), Type (Implanted Heart Pump Device and Extracorporeal Heart Pump Device), Therapy (Bridge-To-Transplant (BTT), Bridge-To-Candidacy (BTC), and Destination Therapy (DT)), End-User (Hospitals, Ambulatory Surgical Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the product segment of the heart pump devices market, left ventricular assist devices (LVAD) under the ventricular assist devices category are expected to hold the largest share and are one of the fastest-growing segments in this market.
It is primarily attributed to the advantages and applications associated with LVAD coupled with increasing technological advancements, the scarcity of organ donors, and the increasing prevalence of heart failure globally.
LVAD is intended for the treatment of patients with severe heart failure by restoring normal blood flow. The implantation of LVAD in heart failure patients can be life-saving and buys more time for them till organ transplantation.
LVADs are highly reliable and come with built-in safety systems.
Post implantation of LVAD, patients witness improvement in their health and can return/resume their daily activities including driving, and others.
LVADs offer intermediate to long-term treatment solutions for severe heart failure patients.
Hence, all the above-mentioned factors are expected to drive the segment growth of the heart pump devices market.
North America is expected to dominate the overall Heart Pump Devices Market:
North America is expected to dominate the overall Heart Pump Devices market during the forecast period. This can be ascribed to the presence of a large patient pool suffering from cardiovascular diseases (CVDs), the highly potent market in terms of product development and launches, high consumer awareness, and the presence of local key market players among other factors in the country, driving the market growth.
The Centers for Disease Control and Prevention (CDC) 2022, estimated that about 20.1 million adults aged 20 and older had Coronary artery disease (CAD) in the US, in 2020.
Also, the same source stated that in the United States, someone has a heart attack every 40 seconds. Every year, about 805,000 people in the United States have a heart attack. Out of these, 605,000 are a first heart attack, 200,000 happen to people who have already had a heart attack and about 1 in 5 heart attacks are silent-the damage is done, but the person is not aware of it.
The increasing number of product development activities in the region is further going to accelerate the growth of the heart pump devices market. For example, in August 2021, the US Food and Drug Administration granted a breakthrough device designation to Abiomed's Impella ECP expandable percutaneous heart pump.
Thus, due to the increase in demand for heart pump devices in the region, there will be a subsequent rise in the growth of heart pump devices regional market during the forecast period.
Heart Pump Devices Market Companies:
Some of the key market players operating in the Heart Pump Devices market include Abbott Laboratories, Abiomed, Inc., Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc. CARMAT, CorWave SA, Medtronic Inc., Terumo Heart, Inc., Calon Cardio-Technology Ltd., NovaPump GmbH, Fresenius Medical Care AG & Co. KGaA, Angiodroid srl, Getinge AB and others.
Recent Developmental Activities in the Heart Pump Devices Market:
In August 2021, the United States Food and Drug Administration (FDA) granted breakthrough device designation to Abiomed's Impella ECP expandable percutaneous Heart Pump. The designation means the FDA will prioritize Impella ECP's regulatory review processes including design iterations, clinical study protocols, and pre-market approval (PMA) application.
In February 2021, CARMAT received FDA approval to conduct an Early Feasibility Study (EFS) of its Total Artificial Heart in the US using BlueSync technology.
In December 2020, Abbott received FDA approval for the updated labeling for the HeartMate 3 Heart Pump to be used in pediatric patients with advanced refractory left ventricular heart failure.
Key Takeaways from the Heart Pump Devices Market Report Study
Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Heart Pump Devices market.
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the Global Heart Pump Devices Market.
Various opportunities are available for the other competitor in the Heart Pump Devices Market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Heart Pump Devices market growth in the coming future?
Target Audience who can be benefited from This Heart Pump Devices Market Report Study
Heart Pump Devices providers
Research organizations and consulting companies
Heart Pump Devices-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders in Heart Pump Devices
Various End-users want to know more about the Heart Pump Devices Market and the latest technological developments in the Heart Pump Devices market.
Frequently Asked Questions for the Heart Pump Devices Market:
What are Heart Pump Devices?
Heart pump devices are utilized in patients that are suffering from heart issues such as a recent cardiac arrest. They carry out the normal functions of the heart by maintaining regular cardiac circulation and replacing the heart partially or completely. After receiving the blood from the heart's lower chambers, it helps transfer the blood to all the vital organs in the body.
What is the market for Global Heart Pump Devices?
Global Heart Pump Devices Market was valued at USD 2.73 billion in 2023, growing at a CAGR of 15.16% during the forecast period from 2024 to 2030, to reach USD 6.35 billion by 2030.
What are the drivers for Global Heart Pump Devices?
The major drivers driving the demand for Heart Pump Devices are the increasing prevalence of cardiovascular diseases, the rising geriatric population, and new product development by the market players.
What are the key players operating in Global Heart Pump Devices?
Some of the key market players operating in the Heart Pump Devices market include Abbott Laboratories, Abiomed, Inc., Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc. CARMAT, CorWave SA, Medtronic Inc., Terumo Heart, Inc., Calon Cardio-Technology Ltd., NovaPump GmbH, Fresenius Medical Care AG & Co. KGaA, Angiodroid srl, Getinge AB and others.
What regions have the highest share in the Heart Pump Devices market?
North America is expected to dominate the overall Heart Pump Devices market during the forecast period, 2024 to 2030. This domination is due to the growing demand for advanced technologies in Heart Pump Devices, the increasing chronic disease in the region is driving the regional growth.